Mystery Adcomm Revealed
This article was originally published in RPM Report
Executive Summary
In 2011, FDA held an unusual closed-door advisory committee meeting on a Phase III product – with Public Citizen’s Sid Wolfe as one panelist. The identity of the drug was finally revealed ahead of a second, open committee meeting.